The UK and US have forged a important trade agreement that will keep no duties on British drug shipments going into the American market.
The Terms of the Deal
As part of the deal, the UK has committed to boost expenditure on drugs through the National Health Service (NHS). This move secures that tariffs on these vital goods will remain at zero for a timeframe of the next three years.
This development is in response to recent threats to dramatically increase tariffs on patented drug imports, with figures floated up to 100%.
"This deal with the UK bolsters the global environment for innovative medicines and establishes much-needed balance to transatlantic pharmaceutical trade," a release noted.
Economic Impact
Medicines constitute one of the UK's most significant goods shipped to the US, which is easily the primary market for large British pharmaceutical firms.
Statistics show that in the year to the end of last September, the UK exported pharmaceutical products valued at billions to the US. This amount made up nearly one-fifth of total UK exports in that period.
"This agreement secures employment, boosts funding and paves the way for the UK to emerge as a international leader for biotech and pharma," a minister commented.
Key British Pledges
The pact involves several notable pledges from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it judges new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a goal to raise total public funding on treatments from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Payback Limit: The percentage drug companies must return to the NHS to stay within budget will be capped at 15%. Last year, repayments exceeded 20%.
Recent Tensions
This agreement comes amid a long-running dispute between the sector and the British authorities over spending levels and regulatory access.
This friction were heightened by claims that US patients were paying several times more for the equivalent treatments than consumers in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been delayed or cancelled, while multi-billion-dollar investments have been announced toward projects in the United States.
A senior figure stated that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had declined as a proportion of its total funding over the past decade.
